<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149528">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01707888</url>
  </required_header>
  <id_info>
    <org_study_id>PEKUPH1201</org_study_id>
    <nct_id>NCT01707888</nct_id>
  </id_info>
  <brief_title>Comparison of Lobectomy and Sublobar Resection for Chinese cT1aN0M0 Peripheral Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 CM) Peripheral Non-Small Cell Lung Cancer in Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Association of Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery may be the best treatment choice for early stage non-small cell lung cancer. And
      Sublobar resection(Wedge resection or anatomic segmentectomy) may be less invasive procedure
      than lobectomy with similar long-term outcome and less risk and improved recovery.There were
      few data of this issue in china.The aim of this study is to investigate the outcome of
      lobectomy versus sublobar resection for small (≤ 2cm) peripheral stage IA non-small cell
      lung cancer (NSCLC) in china.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective randomized LCSG trial of lobectomy versus limited resection for stage IA
      non-small cell lung cancer (NSCLC) disproved sublobar resection as a  comparable surgical
      treatment to lobectomy. However, the role of sublobar resection is still in dispute
      considering the dramatic improvement in radiographic technology, minimal invasive surgical
      technique and significant advances in our understanding of the biology of NSCLC in the
      subsequent 20 years. And Recent meta-analysis revealed survival after limited resection for
      stage I lung cancer was comparable to that after lobectomy. This is a nationwide,
      multicenter, prospective, randomized open phase III study, aimed To evaluate the 5 year
      overall survival (OS) rate of two types of surgery. Patients are stratified according to
      tumor size, histology, smoking status and institutions. Patients are randomized to 1 of 2
      treatment arms.

        -  Arm I: Patients undergo lobectomy by thoracotomy or thoracoscopy/VATS.

        -  Arm II: Patients undergo sublobar resection(wedge resection or anatomical
           segmentectomy) by thoracotomy or thoracoscopy/VATS.

      patients will be followed up every 6 months for 2 years and annually for 5 years
      postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5y</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the 5 year overall survival (OS) rate of two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5y</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate Disease Free Survival (DFS) of two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of loco-regional and systemic recurrence</measure>
    <time_frame>5y</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the rate of loco-regional and systemic recurrence of the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>6 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>to evaluate the pulmonary function as measured by expiratory flow rate of the two groups 6 months postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay.</measure>
    <time_frame>3 months postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluate the postoperative hospital stay of the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative drainage duration</measure>
    <time_frame>3 months postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluate the postoperative drainage duration of the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative morbidity and mortality</measure>
    <time_frame>3 months postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to evaluate the postoperative morbidity and mortality of the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Lobectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo lobectomy by thoracotomy or thoracoscopy/VATS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sublobar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo sublobar resection(wedge resection or anatomic segmentectomy) by thoracotomy or thoracoscopy/VATS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracoscopy/VATS</intervention_name>
    <description>Patients undergPatients undergo lobectomy, wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.</description>
    <arm_group_label>Sublobar</arm_group_label>
    <other_name>Minimal invasive surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracotomy</intervention_name>
    <description>Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.</description>
    <arm_group_label>Lobectomy</arm_group_label>
    <other_name>Open surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70y

          2. Preoperative criteria:

             i) non-small cell lung cancer is suspected, ii) no larger than 2cm in maximal
             diameter, iii) Center of tumor is located in the outer third of the lung field, iv)
             the tumor is not located at middle lobe, v) no hilar and mediastinal lymph node
             metastasis, vi)no pure GGO.

          3. Intraoperative criteria:

             i) Histologically confirmed NSCLC, ii) technically possible to perform any of the
             following procedures: lobectomy, segmentectomy, and nodal dissection.

          4. No prior ipsilateral thoracotomy (prior diagnostic thoracoscopy is allowed).

          5. No prior chemotherapy or radiation therapy for any malignant diseases.

          6. Expected postoperative FEV1.0&gt;=800 mL and PaO2&gt;=65 torr.

          7. Performance status of 0 or 1.

          8. Sufficient organ functions.

          9. preoperative body temperature is 38C or less

         10. Written informed consent.

        Exclusion Criteria:

          1. Active bacterial or fungous infection.

          2. Simultaneous or metachronous (within the past 5 years) double cancers.

          3. Women during pregnancy or breast-feeding.

          4. Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema.

          5. Psychosis.

          6. Systemic steroids medication.

          7. Uncontrollable diabetes mellitus.

          8. Uncontrollable hypertension.

          9. History of severe heart disease, heart failure, myocardial infarction within the past
             6 months or attack of angina pectoris within the past 6 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fan Yang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhao Xi Sui, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Wang, MD</last_name>
    <phone>88324078</phone>
    <email>Jwangmd@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking university people's hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Min Gong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the second Xiangya hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fenglei Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaojie Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou Pulmonary Hospital of Fujian</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zujian Dai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou General Hospital of Nanjing Military Command</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengsheng Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi-Long Wu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoguang Shao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Institute &amp; Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Xu</last_name>
    </contact>
    <investigator>
      <last_name>Lin Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai chest hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heng Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qun Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gening Jiang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3.</citation>
    <PMID>7677489</PMID>
  </reference>
  <reference>
    <citation>Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. Br J Cancer. 2005 Mar 28;92(6):1033-7.</citation>
    <PMID>15756281</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 15, 2012</lastchanged_date>
  <firstreceived_date>October 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Jun Wang</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
